Serum Neurofilament Light Chain Levels in Parkinson’s Disease Therapy: Preliminary Results from a Phase 2 Clinical Trial of Allogenic Bone Marrow-derived Mesenchymal Stem Cell

Systemic AAV Gene Therapy Using a CNS-targeted Engineered Capsid Significantly Increases GCase Activity to Support the Potential Treatment of PD-GBA

Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System Atrophy

Sustained Chorea Improvements with Long-term, Once-daily Valbenazine in Adults with Huntington’s Disease